Heron Therapeutics Reports Q4 Preliminary Net Revenue Of ~$40.5M, ~$154.9M For 2025
Benzinga Newsdesk 10 months ago
News
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.Net revenue of
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.
- Net revenue of approximately $40.5 million for the three months ended December 31, 2025.
- ZYNRELEF® net revenue of approximately $12.5 million for the three months ended December 31, 2025.
- APONVIE® net revenue of approximately $3.8 million for the three months ended December 31, 2025.
- CINVANTI® net revenue of approximately $22.9 million for the three months ended December 31, 2025.
- SUSTOL® net revenue of approximately $1.3 million for the three months ended December 31, 2025.
- Net revenue of approximately $154.9 million for full-year 2025.
- ZYNRELEF® delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4 (up ~35% vs Q3 2025).